Implanon Nxt (Etonogestrel)

Etonogestrel works by binding to progesterone receptors in the brain, suppressing the luteinizing hormone surge that triggers ovulation. It also thickens cervical mucus, creating a barrier to sperm, and alters the uterine lining, reducing the chance of implantation.

The dosage of Implanon Nxt is determined by a qualified healthcare professional. The implant contains a fixed amount of etonogestrel that provides contraceptive effect for up to three years, and the prescriber decides the appropriate use based on individual patient factors.

Implanon Nxt is intended for use in women who are not pregnant. If pregnancy occurs, the implant should be removed. Limited data are available on use during breastfeeding, and healthcare providers typically assess risks and benefits before recommending continuation.

To order Implanon Nxt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with daily oral contraceptives, Implanon Nxt offers a single‑procedure, long‑acting option that eliminates the need for daily adherence. Unlike injectable progestins, the implant provides continuous release for up to three years without repeat injections, and it generally has a lower systemic hormone exposure than some combined methods.

Implanon Nxt should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain its integrity until the time of insertion.

Implanon Nxt is inserted subdermally by a trained healthcare professional. The procedure involves creating a small incision in the upper arm, inserting the pre‑loaded rod, and then closing the site. The implant releases etonogestrel continuously and does not require daily action by the user.

Serious risks include implant migration or extrusion, infection at the insertion site, rare thromboembolic events, severe allergic reactions, and, in very uncommon cases, hormone‑related liver dysfunction. Patients should seek immediate medical attention if they experience signs of infection, unusual pain, or systemic symptoms.

Women with a known hypersensitivity to etonogestrel or any component of the implant, a history of thromboembolic disorders, hormone‑sensitive cancers, or active liver disease should avoid Implanon Nxt. Additionally, it is not recommended for women who are currently pregnant.